According to the latest data from the Hong Kong Stock Exchange, on December 31st, Board Chairman Wu Yifang increased his stake in Everest Medicines (01952) by purchasing 30,000 shares at a price of HK$37.98 per share, amounting to a total investment of HK$1.1394 million. Following this acquisition, his total shareholding has risen to approximately 2.0747 million shares, representing a 0.59% stake in the company.